Advertisement

Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets

  • Ying Chen
  • Yang Deng
  • Miao Yan
  • Zhenyan Hou
  • Yao Li
  • Bikui Zhang
  • Hualin Cai
Original Research Article
  • 68 Downloads

Abstract

Background and Objectives

Risperidone is a derivative of benzisoxazole and is widely used for schizophrenia and other psychiatric illnesses in both adults and children. Previous studies have confirmed that it is a highly variable drug (within-subject variability ≥ 30%). To reduce the large sample size required for bioequivalence researches on highly variable drugs, a role for genotyping in the design of the bioequivalence study was employed.

Methods

A randomized, open-label, two-period crossover study was adopted: 20 subjects with specific genotypes carrying cytochrome P450 (CYP) 2D6*10 were randomized to two groups to receive a single oral dose of trial formulation or reference formulation with a 2-week washout period. Blood concentrations of risperidone (parent drug) and 9-hydroxy risperidone (active metabolite) were measured by high-performance liquid chromatography–tandem mass spectrometry.

Results

Eighteen out of the 20 subjects completed the study (two did not finish the test in the second period). The pharmacokinetic parameters of AUClast, AUC and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively. The CVw of risperidone in natural logarithm-transformed Cmax was 22.4 and 25.38% for 9-hydroxy risperidone.

Conclusions

The test formulation met the Food and Drug Administration guidelines and regulation criteria for bioequivalence. By controlling the genotype, it could actually help reduce the CVw, which may be a feasible method to decrease the sample size for the bioequivalence study of highly variable drugs.

Notes

Acknowledgements

The authors thank all the volunteers who have participated in this study.

Compliance with Ethical Standards

Funding

This work was supported in part by the Nature Science Foundation of China (No. 81401113), the Specialized Research Fund for the Doctoral Program of Higher Education of China (No. 20130162120060), and Hunan Provincial Natural Science Foundation of China (No. 2017JJ3444).

Conflict of interest

The authors declare no conflict of interest in this study.

Ethical approval

The study was conducted in line with GCP, the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the School of Pharmaceutical Sciences, Central South University.

Informed consent

Informed consent was signed by all volunteers before the study.

Supplementary material

13318_2017_459_MOESM1_ESM.pdf (189 kb)
Supplementary material 1 (PDF 188 kb)

References

  1. 1.
    He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol. 1995;10:19–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1998;247:661–70.Google Scholar
  3. 3.
    Chouinard G, Arnott W. Clinical review of risperidone. Can J Psychiatr. 1993;38(Suppl 3):S89–95.Google Scholar
  4. 4.
    Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos. 1993;21(6):1134–41.PubMedGoogle Scholar
  5. 5.
    Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharm J. 2005;5(1):6–13.Google Scholar
  6. 6.
    Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatr. 1994;55(Suppl):13–7.Google Scholar
  7. 7.
    Huang ML, van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257–68.CrossRefPubMedGoogle Scholar
  8. 8.
    Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatr. 1993;38(Suppl 3):S80–8.Google Scholar
  9. 9.
    Cho Hea-Young, Lee Young-Bok. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Arch Pharm Res. 2006;29(6):525–33.CrossRefPubMedGoogle Scholar
  10. 10.
    González-Vacarezza N, Abad-Santos F, Carcas-Sansuan A, Dorado P, Peñas-Lledó E, Estévez Carrizo F, Llerena A. Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6. Pharm J. 2013;13(5):452–5.Google Scholar
  11. 11.
    Cabaleiro T, Ochoa D, Román M, Moreno I, López-Rodríguez R, Novalbos J, Abad-Santos F. Polymorphisms in CYP2D6 have a greater effect on variability of risperidone pharmacokinetics than gender. Basic Clin Pharmacol Toxicol. 2015;116(2):124–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, de Zeeuw RA, Jonkman JH. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol. 1999;55(3):177–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001;51(2):169–73.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    U.S. Department of Health and Human Services, FDA. Guidance for Industry-Bioanalytical method validation. U.S. Department of Health and Human Services, FDA, CDER. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf. Accessed 28 Apr 2015.
  15. 15.
    van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 2003;25(6):1687–99.CrossRefPubMedGoogle Scholar
  16. 16.
    Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R, Meibach R, Heykants J. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology. 1995;122:223–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Huang Mingzhu, Shen-Tu Jianzhong, Xingjiang Hu, Chen Junchun, Liu Jian, Lihua Wu. Comparative fasting bioavailability of dispersible and conventional tablets of Risperidone: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy male Chinese volunteers. Clin Ther. 2012;34(6):1432–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Liu Yun, Zhang Meng-qi, Jia Jing-ying, Liu Yan-mei, Liu Gang-yi, Li Shui-jun, Wang Wei, Weng Li-ping, Chen Yu. Bioequivalence and pharmacokinetic evaluation of two formulations of risperidone 2 mg. Drugs R D. 2013;13(1):29–36.CrossRefPubMedGoogle Scholar
  19. 19.
    Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res. 1999;40(2):101–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, Stelzig Schoeler R, Stuppaeck C, Geretsegger C. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol. 2005;19(4):395–401.CrossRefPubMedGoogle Scholar
  21. 21.
    Cabaleiro T, Ochoa D, Lopez-Rodriguez R, Román M, Novalbos J, Ayuso C, Abad-Santos F. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Hum Psychopharmacol Clin Exp. 2014;29(5):459–69.CrossRefGoogle Scholar
  22. 22.
    Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero Lorenzo C, Fernandez-Piqueras J, Llerena A, Abad-Santos F, Baca-García E, Dal-Ré R, Ayuso C. Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. Pharm J. 2013;13(2):197–204.Google Scholar
  23. 23.
    López-Rodríguez R, Cabaleiro T, Ochoa D, Román M, Borobia AM, Carcas AJ, Ayuso C, Novalbos J, Abad-Santos F. Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics. 2013;14(10):1203–11.CrossRefPubMedGoogle Scholar
  24. 24.
    Yong Chung J, Jung Lee Y, Bok Jang S, Ahyoung Lim L, Soo Park M, Hwan Kim K. CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. Ther Drug Monit. 2010;32(1):67–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Li Xiaobing, Shi Fuguo, He Xiaojing, Jian Lingyan, Ding Li. A rapid and sensitive LC-MS/MS method for determination of lercanidipine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers. J Pharm Biomed Anal. 2016;128:67–72.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacy, The Second Xiangya Hospital, Institute of Clinical PharmacyCentral South UniversityChangshaPeople’s Republic of China
  2. 2.Xiangya School of Pharmaceutical SciencesCentral South UniversityChangshaPeople’s Republic of China
  3. 3.Institute of Clinical PharmacyCentral South UniversityChangshaPeople’s Republic of China
  4. 4.Department of PharmacyThe Third Hospital of Changsha, and The Clinical Application Research Institute of Antibiotics in ChangshaChangshaPeople’s Republic of China

Personalised recommendations